FOR HEALTHCAREPROFESSIONALS
The resources below include information that may help when prescribing XIFAXAN, insurance requirements, and videos about HE. You'll also find materials to share with appropriate patients with HE. These resources may help you get appropriate patients on XIFAXAN, and help them reach your goals for their treatment.
Quickly review some of the recommendations for adult patients with overt HE.
Provides directions for submitting a PA for XIFAXAN when needed.
A standard form for a patient‐specific letter of medical necessity to explain your clinical decision-making in choosing a therapy.
A Tier Exception request to reduce the cost-share of a medication. Follows submission of a PA or Utilization Management request.
HE = hepatic encephalopathy.
AASLD = American Association for the Study of Liver Diseases.
EASL = European Association for the Study of the Liver.
PA = Prior Authorization.
Listen to Dr. Poordad explain the thinking behind the treatment protocol for preventing recurring episodes of overt HE.
Watch Dr. Poordad describe the Phase 3 clinical trial that assessed the efficacy of XIFAXAN in reducing the risk of recurrence for overt HE and HE-related hospitalizations.
See Dr. Flamm explain the reasons for screening patients with cirrhosis for hepatic encephalopathy.
View Dr. Flamm speaking about the importance of recognizing the symptoms of HE on a wide spectrum of neurological and psychiatric manifestations.
Hear Dr. Flamm describe in detail the symptoms of overt HE, from insomnia to full-fledged coma.
Study the face of HE in 4 patients and their caregivers as they describe the toll HE takes on them and their families.
A handy tool to help patients and caregivers recognize the mental and physical symptoms of HE.
Learn about Extra Help/LIS program benefits. Identify the two ways patients can receive Extra Help/LIS benefits. Discover how you can help patients apply for Extra Help/LIS benefits.
Available for eligible,* commercially insured patients.
LIS = Low-income subsidy.
*Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program (each a Government Program), or where prohibited by law. Patient must be enrolled in, and must seek reimbursement from or submit a claim for reimbursement to, a commercial insurance plan. Offer excludes full cash-paying patients. Maximum benefits and other restrictions apply. Visit https://xifaxan.copaysavingsprogram.com/ or call 1-866-XIFAXAN for full eligibility criteria, terms and conditions.
Get information regarding XIFAXAN
Speak with a XIFAXAN representative
Thank you for visiting the XIFAXAN Professional website. By clicking OK, you will be taken to a website or sites where our Privacy Policy and other rules do not apply. Salix Pharmaceuticals does not possess editorial control over the content of the information on such website(s) and therefore does not warrant their accuracy and completeness. You are solely responsible for interactions with such website(s).
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.